Pono Capital Two Inc.

Company Overview

Business Model: SBC Medical Group Holdings Incorporated is a management company that owns, operates, and provides comprehensive management services to cosmetic treatment centers. Its primary revenue generation mechanisms include franchising, procurement, management services, and rental services, predominantly for its network of 241 franchisee treatment centers in Japan. The company also directly owns and operates one treatment center in Ho Chi Minh City, Vietnam, and provides management services to one treatment center in Irvine, California. Following a recent acquisition, it also operates several clinics in Singapore. Services offered through its network include cosmetic surgery, dermatology, and dentistry.

Market Position: The company operates as a single segment, primarily in the highly competitive cosmetic clinic industry. It leverages the "Shonan Beauty Clinic" brand, which originated in Japan in 2000. The company's competitive positioning is based on service quality, patient experience, ambience, location, convenience, value perception, and price. It serves over 6.0 million customers globally, with an average repeat customer rate exceeding 71%. The company aims to expand its brand globally and strengthen its market presence through new clinic development and strategic acquisitions.

Recent Strategic Developments:

• Acquisition of Aesthetic Healthcare Holdings (AHH): In November 2024, SBC Medical Group Holdings Incorporated acquired 100% equity interest in AHH and its subsidiaries in Singapore for SGD$7.8 million (approximately US$5.8 million). This acquisition marks the company's entry into the Singaporean medical aesthetics market, adding brands such as The Chelsea Clinics, Gangnam Laser Clinic, SkinGo!, and Family clinics. AHH's operating results will be consolidated from 2025.
• Upcoming Changes to Service Fee Structure: Effective April 1, 2025, the service fee structure for newly opened clinics will be revised, with reduced fees in the first year, then based on service utilization. This change is estimated to have decreased 2024 total revenues by approximately 10% if applied, but is expected to be offset in 2025 by the absence of one-time losses.
• Upcoming Insurance Policy Maturity: Corporate-owned life insurance policies for the CEO and a key officer are set to mature on March 29, 2025, with an expected gain on surrender of approximately $9.3 million in Q1 fiscal year 2025.
• Disposal of Non-Core Assets: In December 2024, the company disposed of Kijimadairakanko Inc. and Skynet Academy Co., Ltd. for JPY 1 ($0) and JPY 70,000,000 ($446,460) respectively, to entities controlled by the CEO. These disposals were aimed at concentrating on the core medical business.

Geographic Footprint: The company's primary operations and over 90% of its revenue are derived from management services to Medical Corporations operating in Japan. It also has an owned treatment center in Ho Chi Minh City, Vietnam, provides management services to a treatment center in Irvine, California, and, following the AHH acquisition, operates several clinics in Singapore.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 75.97% (2024) vs. 70.94% (2023)
• Operating Margin: 34.23% (2024) vs. 36.51% (2023)
• Net Margin: 22.73% (2024) vs. 20.34% (2023)

Investment in Growth:

• R&D Expenditure: Not explicitly stated as a separate line item.
• Capital Expenditures: $2,564,643 (2024) vs. $8,543,351 (2023)
• Strategic Investments: Acquisition of Aesthetic Healthcare Holdings for approximately $5.8 million in November 2024. Purchase of a convertible note for $1,700,000 in 2024.

Business Segment Analysis

SBC Medical Group Holdings Incorporated operates as a single operating segment, providing comprehensive management services to Medical Corporations and their clinics.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: 270,000 common shares were recorded as treasury stock upon the conversion of a $2,700,000 promissory note in September 2024.
• Dividend Payments: No cash dividends have been paid, and none are anticipated in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific authorized programs disclosed.

Balance Sheet Position (as of December 31, 2024):

• Cash and Equivalents: $125,044,092
• Total Debt: $6,599,506
• Net Cash Position: $118,444,586
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Weighted average years to maturity of 2.91 years, with a weighted average interest rate of 1.20%. Key maturities include $96,824 in 2025, $66,580 in 2026, and $6,436,102 in 2027.

Cash Flow Generation:

• Operating Cash Flow: $20,582,933 (2024) vs. $50,670,322 (2023)
• Free Cash Flow: $18,018,290 (2024) vs. $42,126,971 (2023)
• Cash Conversion Metrics: Not explicitly detailed in the filing.

Operational Excellence

Production & Service Model: SBC Medical Group Holdings Incorporated provides comprehensive management services to Medical Corporations (MCs) and their clinics. These services encompass advertising, staff management, booking reservations, housing and facility rentals, construction and design, procurement of medical equipment and consumables, provision of cosmetic products, IP and technology licensure, IT solutions, customer rewards program management, and payment tools. The company focuses on enhancing staff skills, standardization, and education through technology.

Supply Chain Architecture: Key Suppliers & Partners:

• Medical Supplies: The company utilizes a large and diverse network of suppliers for medical devices, equipment, implants, injection materials, and other medical consumables. It maintains multiple suppliers for key categories to mitigate sourcing risks. Payment terms are typically open account with credit periods ranging from 20 to 60 days. No major sourcing problems or disruptions were encountered.

Facility Network:

• Headquarters: Irvine, CA (215 sq ft, lease expires 07/01/2025).
• Manufacturing: Not applicable, as the company provides services and management.
• Research & Development: R&D activities are focused on developing and licensing simulation technology, including AI-driven tools for staff training and service enhancement.
• Distribution: The company operates an equipment warehouse in Japan (1,843 sq ft). Its service delivery model relies on its network of 241 franchisee treatment centers in Japan, an owned center in Vietnam, a managed center in the US, and acquired clinics in Singapore. Average franchisee clinic size is approximately 357 square feet, with new clinic construction taking about 6 months and an average cash build-out cost of approximately $333,000 per clinic in fiscal year 2024.
• Other Leased Facilities: Extensive leased office spaces, call centers, and a beauty salon/lounge primarily in Tokyo, Osaka, Sendai, and Kanagawa, Japan, and a clinic and office in Singapore.

Operational Metrics:

• Average Repeat Customer Rate: Over 71%
• Total Customers Globally (2024): Over 6.0 million
• Total Users (2024): Approximately 3.9 million

Information Security & Cybersecurity: The Information Systems Department manages network construction and cybersecurity. Key issues addressed include malware infection (mitigated by email training and detection products), vulnerabilities (assessed for public services), ransomware (multiple backups and recovery procedures), information leaks, and Denial of Service (DOS) attacks (prevented by WAF). Cybersecurity matters are reported to the board of directors for approval and oversight. Employee training includes annual cybersecurity response, recovery simulation, and malicious attack simulations. The company plans to establish selection and management policies for third-party service providers.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: The company provides management services directly to Medical Corporations (MCs) which operate the clinics.
• Digital Platforms: Leverages advertising and marketing services, including social media platforms like Instagram and YouTube, to attract customers. It also utilizes IT software solutions for remote medical consultations and booking reservations.
• Channel Partners: The company's primary channel is its extensive network of franchisee treatment centers.

Customer Portfolio: Enterprise Customers: The company's primary "customers" are the Medical Corporations (MCs) to which it provides management services.

• Customer Concentration: In 2024, Customer A accounted for 26% of total revenues, Customer B for 23%, and Customer C for 23%. As of December 31, 2024, accounts receivable concentration included Customer A (17%), Customer B (28%), Customer C (26%), and Customer D (10%). This indicates a significant reliance on a few key MCs.
• Strategic Partnerships: The company has long-standing relationships with various MCs, some of which are related parties.

Geographic Revenue Distribution:

• Japan: Over 90% of total revenue is derived from management services to MCs primarily operating in Japan.
• Growth Markets: The company has operations in Vietnam, Singapore (following the AHH acquisition), and the United States, indicating a strategy for international expansion.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The cosmetic clinic industry is highly competitive, characterized by numerous entrants. Demand is significantly influenced by patient preferences, with a growing trend towards non-invasive services. General economic conditions, including discretionary income and inflation, and demographic trends (e.g., younger and middle-aged generations' willingness for elective procedures) are key drivers of market demand.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The cosmetic clinic industry faces competition from a wide array of global players including Aesthetic Medispa, Alma Lasers, B. Braun SE, Cynosure Aesthetics, Evolus, Inc., Galderma S.A., Genesis Biosystems, Inc., Inmode Ltd., IRIDEX Corporation, Lumenis Be Ltd., Revance Therapeutics, Inc., Sientra, Inc., Sinclair Pharma Limited, Stryker Corporation, and Surgery Partners. Competition is primarily based on service quality, patient experience, ambience, location, convenience, value perception, and price.

Emerging Competitive Threats: The filing notes the industry's high number of entrants and the influence of evolving patient preferences, suggesting a dynamic competitive landscape where new technologies or service models could emerge.

Competitive Response Strategy: SBC Medical Group Holdings Incorporated's strategy involves strengthening its brand, offering comprehensive medical services, leveraging technology (such as AI simulation), and maintaining robust internal processes and protocols. The company pursues new clinic development, aims for comparable franchisee clinic sales growth, seeks to increase profitability by leveraging its infrastructure, heightens brand awareness through marketing, and invests in procedure and product development.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company is dependent on the performance of its operating subsidiaries and franchisees for cash flows. Growth of the franchise system carries inherent risks, and negative franchisee financial performance could adversely impact the company. The cosmetic clinic industry is highly competitive, and demand is sensitive to general economic conditions and patient preferences.

• Technology Disruption: Risks related to the inability to protect intellectual property and the need for continuous innovation to maintain a competitive edge.
• Customer Concentration: Significant revenue and accounts receivable concentration with a few key Medical Corporations (MCs) poses a dependency risk.
• Brand Dependence: Dependence on the "Shonan Beauty Clinic" brand, making it vulnerable to adverse publicity or reputational damage.
• International Expansion: Limited international experience poses risks in new markets.

Operational & Execution Risks

Supply Chain Vulnerabilities: While the company maintains a diverse supplier network, any significant disruption to key suppliers of medical devices, equipment, or consumables could impact operations.

• Employee Misconduct: A material risk highlighted by the misappropriation of approximately JPY 632 million ($5.6 million) by a former manager between April 2016 and January 2024.
• Cybersecurity Incidents: Risks of cybersecurity incidents or disruptions to operating systems, including malware, ransomware, information leaks, and Denial of Service (DOS) attacks.
• Regulatory Compliance (MCs): Limited control over MC operations and the risk of MCs failing to comply with the Medical Care Act in Japan.
• Internal Control Weaknesses: Material weaknesses in internal control over financial reporting were identified, including an ineffective control environment, insufficient control activities, absence of an effective risk assessment process, inadequate communication, and ineffective monitoring controls. Post-business combination, additional weaknesses include insufficient controls for related party transactions and lack of adequate financial reporting personnel.

Financial & Regulatory Risks

Market & Financial Risks: Significant capital requirements for business plans and risks associated with strategic alliances or acquisitions.

• Foreign Exchange: Exposure to foreign currency exchange rate fluctuations, particularly between JPY and US$.
• Litigation Exposure: Potential for litigation, product liability claims (though the company does not manufacture products), and limited insurance coverage.

Regulatory & Compliance Risks: The company and its MCs are subject to extensive and complex regulations across Japan, Vietnam, the United States, and Singapore, covering public/occupational health and safety, product labeling, healthcare, environmental laws, information security, privacy, cashless payments, import laws, and tariffs. Changes in these regulations or non-compliance could lead to increased costs or penalties.

Geopolitical & External Risks

Geopolitical Exposure: Global economic conditions, natural disasters, and health epidemics can impact demand for elective services.

• Trade Relations: Potential impact from trade tariffs or barriers in international markets.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Simulation Technology: SBC Medical Group Holdings Incorporated develops and licenses advanced simulation technology, incorporating virtual reality, rendering, computing, 5G/6G, and Web3.0. This technology utilizes medical cases and AI to enhance staff skills, standardize procedures, and improve education.
• AI-driven Solutions: A key innovation is "SBC AI Eye," a double AI simulation service based on 600,000 double layer cases, aimed at improving cosmetic procedure outcomes.

Intellectual Property Portfolio:

• Patent Strategy: As of December 31, 2024, the company has filed numerous patent and trademark applications in Japan and with the International Bureau of the World Intellectual Property Organization. It holds registered patents and trademarks in Japan, including "SBC," "Shonan Beauty Clinic," "SBCLABO," "Hair Renaissance," "SBC MEDISPA," and "ACNEED." The Singapore subsidiary holds trademarks in Singapore. No registered IP in Vietnam or the United States.
• Licensing Programs: The company licenses its patent-pending and non-patented IP, including medical technologies and safety management methods, to Medical Corporations (MCs). MCs pay monthly royalties ranging from JPY 14,000,000 to JPY 53,000,000 for trademarks and JPY 700,000 to JPY 53,000,000 for patents. Total annual royalties from MCs amount to JPY 273,900,000.

Technology Partnerships:

• Strategic Alliances: Not explicitly detailed in the filing, but the licensing model implies a collaborative relationship with MCs for technology deployment.

Leadership & Governance

Executive Leadership Team